Mylan NV (NASDAQ:MYL)
About the company
Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.
Gross Margin (in %)
Operating Margin (in %)
Net Margin (in %)
Dividend Yield (in %)
|Name||Ticker||Market capitalization (in USD Million)||Revenues (in USD Million)||Price/Book||Price/Earning||Net margin (in %)|
|BridgeBio Pharma, Inc.||BBIO||3590.07||41.00||9.45||-12.36||-718.08|
|Taro Pharmaceutical Industries Ltd.||TARO||2591.60||645.00||1.24||10.74||37.88|
|Abeona Therapeutics, Inc.||ABEO||210.92||3.00||2.15||-2.07||75.95|
|Kindred Biosciences, Inc.||KIN||157.56||4.00||2.62||-2.31||None|
|Cocrystal Pharma, Inc.||COCP||53.55||2.00||1.96||-0.92||-733.84|
|China Pharma Holdings, Inc.||CPHI||26.40||10.00||3.16||-1.22||-214.63|
|Jaguar Health, Inc.||JAGX||4.92||5.00||3.64||0.08||-887.14|
Latest insider transactions
|Date||Role||Name||Transaction||Quantity||Quantity Owned After|
Mylan NV said on Monday it would launch a generic version of Gilead Sciences Inc's COVID-19 antiviral remdesivir in India at ...
Mylan NV has received approval from DCGI to manufacture and market its remdesivir for restricted emergency use in the country ...
Mylan's version comes after two Indian drugmakers, Cipla Ltd and privately-held Hetero Labs Ltd, launched their generic ...
Mylan to manufacture Remdesivir in India at its injectables facilities.Drug has been approved in India for treatment of ...
"Developing Desrem and bringing it to patients in India with such unprecedented speed is a testament to the strength of our global operations and scientific capabilities and our commitment to serving ...
Mylan will manufacture Remdesivir in India at its world-class injectables facilities, which also make product for the US and ...
Per 100 mg vial to cost Rs 4,800; Cipla and Hetero have also got permission to manufacture and market the drug for the treatment of COVID-19 Pharmaceutical major Mylan NV on Monday said it had ...